JIPOAd
PARP
ESID
  • Users Online: 361
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Citation statistics : Table of Contents
   2019| July-September  | Volume 2 | Issue 3  
    Online since August 22, 2019

 
 
  Archives   Previous Issue   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Cited Viewed PDF
EDITORIAL
Cancer immunotherapy for the immunosuppressed: Dissecting the conundrum of safety and efficacy
Joud Hajjar
July-September 2019, 2(3):53-54
DOI:10.4103/JIPO.JIPO_15_19  
  2 599 87
CASE REPORT
Eosinophilic fasciitis in a patient treated by atezolizumab for metastatic triple-negative breast cancer
Yacine Wissam, Laila Belcaid, Ruth Wittoek, Vanessa Smith, Amber Vanhaecke, Sofie De Schepper, Lennart Jans, Daphné t'Kint de Roodenbeke, Andrea Gombos, Sandrine Aspeslagh
July-September 2019, 2(3):101-105
DOI:10.4103/JIPO.JIPO_8_19  
  - 668 36
CONFERENCE PROCEEDINGS
Meeting Proceedings of the First Immuno-Oncology Society of India Conference (I-OSICON-2019), Mumbai, India
Jyoti Bajpai, Ram Abhinav Kannan, Hemant Malhotra, Vivek Radhakrishnan, Rakesh Jalali, Gaurav Narula, Amit Awasthi, Girdhari Lal, Rahul Purvar, Kumar Prabhash, Senthil Rajappa, Atul Sharma, Moni Kuriakose, Vikram Matthews, Reena Nair, Smruti Koppikar, Shubhda V Chiplunkar, Shripad Banavali
July-September 2019, 2(3):106-125
DOI:10.4103/2666-2345.265156  
  - 462 46
EXPERT OPINION
Immunotherapy use in patients with HIV and non-small-cell lung cancer: Current data
Katherine A Scilla, Alessandro Russo, Christian Rolfo
July-September 2019, 2(3):55-58
DOI:10.4103/JIPO.JIPO_13_19  
  - 872 64
ORIGINAL RESEARCH
Safety of immune checkpoint blockade in patients with cancer and preexisting autoimmune diseases and/or chronic inflammatory disorders
Mohsin Shah, Mazen N Jizzini, Imad E Majzoub, Aiham Qdaisat, Cielito C Reyes-Gibby, Sai-Ching Yeung
July-September 2019, 2(3):59-64
DOI:10.4103/JIPO.JIPO_11_19  
  - 724 76
Rheumatic and musculoskeletal adverse events with immune checkpoint inhibitors: Data from the United States Food and Drug Administration adverse event reporting system
Xerxes N Pundole, Mayur Sarangdhar, Maria E Suarez-Almazor
July-September 2019, 2(3):65-73
DOI:10.4103/JIPO.JIPO_12_19  
  - 667 63
REVIEW ARTICLES
Kaposi's sarcoma in the immunosuppressed
Nisha A Reddy, Steven R Mays, Omar Pacha
July-September 2019, 2(3):74-78
DOI:10.4103/JIPO.JIPO_10_19  
  - 715 53
Common cutaneous neoplasms in patients with immunodeficiency: A case series
Suhair Al Salihi, Haider A Mejbel, Victor G Prieto, Phyu P Aung
July-September 2019, 2(3):79-84
DOI:10.4103/JIPO.JIPO_9_19  
  - 422 27
Review: The impact of HIV infection on cancer treatment with immunotherapy
Bruno Palma Granwehr
July-September 2019, 2(3):85-92
DOI:10.4103/JIPO.JIPO_14_19  
  - 316 23
Neuromuscular weakness syndromes from immune checkpoint inhibitors: A case series and literature review
Ahmad Daher, Carlos Kamiya Matsuoka, Monica Elena Loghin, Marta Penas-Prado, Sudhakar Tummala
July-September 2019, 2(3):93-100
DOI:10.4103/JIPO.JIPO_3_19  
  - 711 55